Less than one in 10 individuals that would benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it issues its inaugural guidance on the therapies.
Considering over a billion people worldwide currently living with obesity, it is calling for broader and more equitable access to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our new guidelines acknowledges that obesity is a long-term condition that can be treated with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to widespread access to the injections that can assist patients in reducing considerable body mass, explains the body.
GLP-1 Therapy Shortage
Even under the present most optimistic scenario, the supply of these medications would only suffice for about 100 million people – less than 10% of those who need them, per the WHO.
The guideline urges nations and manufacturers to increase access, through measures including voluntary licensing.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so users consume fewer calories.
Individuals typically see weight reduction within a few weeks of beginning the regular doses.
Studies suggests people may see weight return a year later of discontinuing the medication, when their normal hunger resume.
To be above a healthy weight elevates your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects people in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
